Abstract
Objective: To evaluate the efficacy of ulipristal acetate in reducing the volume of large uterine fibroids in patients undergoing conservative treatment. Material and methods: A prospective, observational, and longitudinal study was conducted in patients diagnosed with large uterine myomatosis at the Hospital General de Zona No. 20 of the IMSS, Puebla. Ulipristal acetate (5 mg/day) was administered for 3 months. Pregnant, postpartum, or lactating patients, those with hypersensitivity to the drug, or those with liver diseases were excluded. Basal and follow-up pelvic ultrasounds were performed to evaluate fibroid dimensions. Results: 57 patients participated, with a mean age of 36 years (30–53 years). 63.2% were overweight and 28.1% were obese. 64.9% had submucosal fibroids, and 33.3% required blood transfusion. No statistically significant differences were observed in the size of the fibroids before and after treatment (p = 0.290 and p = 1.00). Conclusion: Ulipristal acetate at a dose of 5 mg/day for 3 months did not show efficacy in reducing the size of large-volume uterine fibroids.
Introduction
Uterine fibroids, or leiomyomas, represent the most prevalent benign tumors among women of reproductive age. These growths frequently result in significant clinical burdens, including heavy menstrual bleeding, pelvic pain, and infertility. While surgical interventions like hysterectomy or myomectomy remain the standard of care, there is a growing demand for pharmacological alternatives that allow for fertility preservation and avoid surgical risks.
Ulipristal Acetate (UA), a Selective Progesterone Receptor Modulator (SPRM), has been recognized internationally as a promising non-surgical option. However, clinical outcomes often vary across different ethnic and geographic populations. This study investigates the efficacy of UA specifically for "large elements"—fibroids measuring 5 cm or larger—within a Mexican patient population, a demographic often characterized by specific metabolic profiles.
Methods
This prospective, longitudinal, quasi-experimental study was conducted at the Hospital General de Zona No. 20 (IMSS) in Puebla, Mexico. The cohort included 57 women (median age 36) diagnosed with large fibroids (≥5 cm) who opted for conservative management.
Participants received a daily oral dose of 5 mg of Ulipristal Acetate for three consecutive months. The primary outcome measure was the change in the linear dimensions (width and length) of the largest fibroid, assessed via transvaginal pelvic ultrasound at baseline and following the treatment course. Data analysis utilized descriptive statistics and the non-parametric Mann-Whitney U test to compare pre- and post-treatment measurements. Anthropometric data (BMI), obstetric history, and clinical symptoms (e.g., bleeding severity) were also recorded.
Results
The study population exhibited a high prevalence of metabolic comorbidities, with 91.3% of participants classified as either overweight or obese. Clinical symptoms were severe: 100% of participants reported abnormal uterine bleeding, and 33.3% required at least one blood transfusion prior to or during the study period.
Regarding the primary endpoint, the treatment failed to achieve significant volume reduction:
- Median Width: Remained at 6.5 cm (p = 0.290).
- Median Length: Remained at 6.9 cm (p = 1.000).
Despite the lack of morphological regression, the treatment was well-tolerated. No major adverse events were reported among the 57 participants, confirming the safety profile of the 5 mg daily dose for short-term use in this specific population.
Discussion and Conclusion
The findings suggest that a standard three-month regimen of 5 mg/day of Ulipristal Acetate may be insufficient for treating large fibroid masses (≥5 cm). This contrasts with some European trials where UA showed greater efficacy, suggesting that geographic and ethnic factors—particularly high BMI and associated chronic inflammation—may influence the therapeutic response to SPRMs.
The study's reliance on 2D ultrasound linear measurements may have overlooked subtle volumetric changes that 3D ultrasound or MRI could detect. Furthermore, the three-month duration might be too brief for significant regression of large elements. Future research should explore extended treatment cycles, higher dosages, or combination therapies (e.g., with GnRH analogs) to improve outcomes for this patient group.
In conclusion, while Ulipristal Acetate is a safe pharmacological tool, its efficacy as a primary volume-reduction agent for large fibroids in populations with high metabolic risk factors appears limited under standard short-term protocols.
Summary updated